Investigational — This vaccine is not yet approved for general use. Information is for educational purposes only. Participation in clinical trials requires enrolment at an authorised trial centre.
DCVax-L
Also known as: Dendritic cell vaccine GBM · personalised DC vaccine · NW Biotherapeutics GBM vaccine
DCVax-L is a personalised dendritic cell vaccine for glioblastoma — the most aggressive primary brain tumour with a median survival of just 15 months on standard-of-care (Stupp protocol). The Phase 3 trial (n=331), conducted across US, UK, Germany, Canada, and Australia, showed that patients receiving DCVax-L alongside standard chemotherapy (temozolomide) lived a median of 19.3 months vs 16.5 months for placebo — and more strikingly, 13% of DCVax-L patients were still alive at 5 years versus 5.7% of controls. In a disease where 5-year survival is almost unheard of, this long-tail survival benefit has attracted significant attention. Published in JAMA Oncology in 2023 after being one of the most anticipated oncology trial results in years.
What It Targets
Target Antigen
Patient's own tumour lysate (all tumour antigens presented simultaneously)
Cancers Targeted
How It Works
Patient's GBM tumour is surgically removed → tumour is processed into a lysate containing all tumour-associated antigens → patient's own dendritic cells (collected via leukapheresis from blood) are pulsed with the tumour lysate for 3 days in the lab → activated dendritic cells, now loaded with tumour antigens, are injected back into the patient intradermally → dendritic cells migrate to lymph nodes and prime CD4+ and CD8+ T cells against the patient's specific tumour → systemic anti-tumour immune response is generated. The vaccine is repeated every 8 weeks to maintain immune activation.
Key Trial Results
- Phase 3 (n=331): median overall survival 19.3 months (DCVax-L) vs 16.5 months (placebo) — 2.8 month improvement in median
- Critically: 13% alive at 5 years (DCVax-L) vs 5.7% (control) — the long-tail benefit is the headline finding
- New GBM patients: 19.6 vs 16.5 months; recurrent GBM: 13.2 vs 7.8 months
- JAMA Oncology 2023: peer-reviewed publication validated trial conduct and results
- MGMT-methylated subgroup: strongest benefit — 31% alive at 5 years in DCVax-L arm
- UK MHRA: Northwest Biotherapeutics initiated regulatory engagement post Phase 3
- Compassionate use access being explored in selected UK and EU neurosurgery centres
Regulatory Status & Availability
Approval Status
Phase 3 trial completed (NWBO). Results published in JAMA Oncology (2023). Conditional approval discussions with EMA/MHRA underway.
Estimated Availability
UK: MHRA reviewing; EU: EMA engagement ongoing. US: not yet FDA-approved. Compassionate use in some EU centres.
Important Considerations
- Modest median survival benefit (2.8 months) — the long-tail 5-year benefit is compelling but affects a minority of patients
- Manufacturing is complex and patient-specific — requires fresh tumour at resection and blood leukapheresis
- Not yet FDA or EMA approved — access currently through clinical trials or compassionate use programs
- MGMT methylation status strongly influences benefit — genetic testing of tumour required
- Manufacturing logistics need to be coordinated at diagnosis, before starting temozolomide
Research References
iOnco provides this information for educational purposes only. Cancer vaccine availability, trial eligibility, and access pathways change frequently. Always discuss vaccination decisions and clinical trial participation with your oncologist or healthcare provider.